Ken Griffin Taysha Gene Therapies, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.01 - $2.46 $11,054 - $13,530	-5,500 Reduced 34.59%	10,400 $20,000
Q2 2024 Aug 14, 2024	SELL	$2.04 - $4.17 $100,572 - $205,581	-49,300 Reduced 75.61%	15,900 $35,000
Q1 2024 May 15, 2024	BUY	$1.43 - $3.25 $51,337 - $116,675	35,900 Added 122.53%	65,200 $187,000
Q4 2023 Feb 14, 2024	SELL	$1.33 - $2.88 $266 - $576	-200 Reduced 0.68%	29,300 $51,000
Q3 2023 Nov 14, 2023	BUY	$0.63 - $3.66 $17,640 - $102,480	28,000 Added 1866.67%	29,500 $93,000
Q2 2023 Aug 14, 2023	SELL	$0.59 - $0.87 $177 - $261	-300 Reduced 16.67%	1,500 $0
Q1 2023 May 15, 2023	SELL	$0.65 - $2.3 $30,875 - $109,249	-47,500 Reduced 96.35%	1,800 $1,000
Q4 2022 Feb 14, 2023	SELL	$1.39 - $2.98 $46,009 - $98,638	-33,100 Reduced 40.17%	49,300 $111,000
Q3 2022 Nov 14, 2022	BUY	$1.76 - $4.94 $104,544 - $293,436	59,400 Added 258.26%	82,400 $159,000

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $97.2M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.